BOSTON, April 3, 2019 /PRNewswire-PRWeb/ -- LeadingBiotech, an exclusive event series bringing biopharma CEOs and leaders together though intimate off-the-record collaboration and dialogue, today announces its Boston CEO conference to be held May 28-29, 2019 at Boston's Four Seasons Hotel. Boston CEO offers insights into the industry's challenges and opportunities with high-level panels and discussions from past, present and future change-makers.
LeadingBiotech, formerly Boston Biotech Conferences, is moving in a new direction, creating a reinvigorated experience for senior leaders. "Our CEO event series has evolved to offer an even better experience for our attendees to inform business strategies and set industry agendas," explained LeadingBiotech CEO Wendy Nelson, Ph.D. "The event's mission is to share ideas, compare experiences and speak candidly through off-the-record dialogue."
Highlights of this year's conference include a special fireside chat titled: Navigating A New Frontier in Biotech – what is the industry facing now and in the future? From consolidation in healthcare to the impact of med tech and data science on how medicines are consumed, the biotech industry is launching into a different world. The discussion offers insights into the question: In a time of seismic shifts and tremendous change, how do we make sure the cost of innovation also leads to better care? Featured speakers include Jeremy M. Levin, D.Phil, MB BChir,?Chairman & CEO, Ovid Therapeutics Ovid Therapeutics; Bruce Booth, D.Phil, Partner, Atlas Venture; and Andy Plump, M.D., Ph.D., President, R&D, Takeda Pharmaceutical Co., Ltd.
"I'm delighted to be a part of Boston CEO's impressive lineup of discussions and look forward to participating in the fireside chat on industry change, innovation and the impact on patient care," said Jeremy M. Levin, D.Phil, MB BChir, Chairman & Chief Executive Officer, Ovid Therapeutics. "Boston CEO is a great opportunity to collaborate with some of Boston's key industry leaders."
Keynote speakers at this year's event include:
Jeff Jonas, M.D., Chief Executive Officer, Sage Therapeutics Laurie Glimcher, M.D., President & CEO, Dana Farber Cancer Institute George Church, Ph.D., Professor of Genetics, Department of Genetics, Harvard Medical School Michael Sherman, M.D., Chief Medical Officer and Sr. VP, Harvard Pilgrim Health Care John Glasspool - Chief Executive Officer, Anthos Therapeutics
Additional keynote and panel topics at the conference include:
A Digital Revolution: Biotech's Convergence with Data Science Building Effective Partnerships to Advance New Drugs Keynote: Technologies for Reading & Editing Genomes Exit Dynamics in 2019: M&As vs IPOs Fireside Chat: Raising Money Non-Traditionally Patient Engagement & Advocacy
Please find our complete agenda here: https://bit.ly/2GrYgNz
About LeadingBiotech Formerly known as Boston Biotech Conferences, LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We're working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more, please visit: https://leadingbiotech.com/.
SOURCE LeadingBiotech
Advertisement
LeadingBiotech, formerly Boston Biotech Conferences, is moving in a new direction, creating a reinvigorated experience for senior leaders. "Our CEO event series has evolved to offer an even better experience for our attendees to inform business strategies and set industry agendas," explained LeadingBiotech CEO Wendy Nelson, Ph.D. "The event's mission is to share ideas, compare experiences and speak candidly through off-the-record dialogue."
Advertisement
Highlights of this year's conference include a special fireside chat titled: Navigating A New Frontier in Biotech – what is the industry facing now and in the future? From consolidation in healthcare to the impact of med tech and data science on how medicines are consumed, the biotech industry is launching into a different world. The discussion offers insights into the question: In a time of seismic shifts and tremendous change, how do we make sure the cost of innovation also leads to better care? Featured speakers include Jeremy M. Levin, D.Phil, MB BChir,?Chairman & CEO, Ovid Therapeutics Ovid Therapeutics; Bruce Booth, D.Phil, Partner, Atlas Venture; and Andy Plump, M.D., Ph.D., President, R&D, Takeda Pharmaceutical Co., Ltd.
"I'm delighted to be a part of Boston CEO's impressive lineup of discussions and look forward to participating in the fireside chat on industry change, innovation and the impact on patient care," said Jeremy M. Levin, D.Phil, MB BChir, Chairman & Chief Executive Officer, Ovid Therapeutics. "Boston CEO is a great opportunity to collaborate with some of Boston's key industry leaders."
Keynote speakers at this year's event include:
Jeff Jonas, M.D., Chief Executive Officer, Sage Therapeutics Laurie Glimcher, M.D., President & CEO, Dana Farber Cancer Institute George Church, Ph.D., Professor of Genetics, Department of Genetics, Harvard Medical School Michael Sherman, M.D., Chief Medical Officer and Sr. VP, Harvard Pilgrim Health Care John Glasspool - Chief Executive Officer, Anthos Therapeutics
Additional keynote and panel topics at the conference include:
A Digital Revolution: Biotech's Convergence with Data Science Building Effective Partnerships to Advance New Drugs Keynote: Technologies for Reading & Editing Genomes Exit Dynamics in 2019: M&As vs IPOs Fireside Chat: Raising Money Non-Traditionally Patient Engagement & Advocacy
Please find our complete agenda here: https://bit.ly/2GrYgNz
About LeadingBiotech Formerly known as Boston Biotech Conferences, LeadingBiotech is an event series that brings biopharma CEOs and leaders together through intimate, off-the-record collaboration. We're working hard to create more valuable experiences to re-energize collaboration and infuse fresh ideas to better shape the future of biotech. For more, please visit: https://leadingbiotech.com/.
SOURCE LeadingBiotech
